BICO Group AB
STO:BICO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BICO Group AB
Cash Equivalents
BICO Group AB
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BICO Group AB
STO:BICO
|
Cash Equivalents
kr1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Cash Equivalents
kr813m
|
CAGR 3-Years
29%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Cash Equivalents
kr420m
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
G
|
Genovis AB
STO:GENO
|
Cash Equivalents
kr163.2m
|
CAGR 3-Years
31%
|
CAGR 5-Years
30%
|
CAGR 10-Years
55%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Cash Equivalents
kr370.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
18%
|
|
BICO Group AB
Glance View
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
See Also
What is BICO Group AB's Cash Equivalents?
Cash Equivalents
1.2B
SEK
Based on the financial report for Dec 31, 2025, BICO Group AB's Cash Equivalents amounts to 1.2B SEK.
What is BICO Group AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
22%
Over the last year, the Cash Equivalents growth was 27%. The average annual Cash Equivalents growth rates for BICO Group AB have been 9% over the past three years , 22% over the past five years .
